“The cynomolgus monkey is a relevant species for toxicology studies based on glofitamab binding to CD20 and CD3 on cynomolgus monkey B- and T-cells.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Why that species
Comparable binding to human and monkey B- and T-cells (EC50 4.3/2.3 nM B, 21.1/13.2 nM T); no rodent, dog, minipig cross-reactivity
“Glofitamab bound to human and monkey B-cells with EC50 values of 4.3 and 2.3 nM respectively and bound to human and monkey T-cells with EC50 values of 21.1 and 13.2 nM respectively. This justified use of the cynomolgus monkey for general toxicology studies.”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗
Surrogate molecule
No surrogate; clinical molecule tested in monkey (obinutuzumab pretreatment used in some studies)
“The cynomolgus monkey is a relevant species for toxicology studies based on glofitamab binding to CD20 and CD3 on cynomolgus monkey B- and T-cells.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗